Advancements in Tuberculosis Management: A Comprehensive Review of Novel Diagnostics, Drug Regimens, and the Challenge of Drug Resistance

1.1 Global Burden and Epidemiology of TB

Tuberculosis (TB) is an infectious bacterial disease that most commonly affects the lungs, though it can affect any part of the body. Historically known as "consumption" or the "white plague," it continues to be a major global health concern. According to the World Health Organization (WHO), TB is second only to COVID-19 as a cause of death from a single infectious agent, surpassing HIV/AIDS. The disease disproportionately affects low- and middle-income countries, particularly in Southeast Asia and Africa, although no nation is entirely free from its presence.

The persistent nature of TB as a pandemic is attributed to factors like poverty, malnutrition, densely populated living conditions, and the alarming co-epidemic of Human Immunodeficiency Virus (HIV). Global efforts, including the WHO's "End TB Strategy," aim to reduce TB incidence by 90\% and TB deaths by 95\% by 2035, compared to 2015 levels. Pharmacists and pharmaceutical scientists play a crucial role in achieving these targets through research into new drugs and improvements in therapeutic compliance  [1]  .

1.2 Etiology: Mycobacterium tuberculosis (Mtb)

Tuberculosis is caused by bacteria of the Mycobacterium tuberculosis complex (MTBC), with M. tuberculosis being the causative agent in the vast majority of human cases. Mtb is a small, non-motile, rod-shaped bacillus characterized by its unique cell wall, which is rich in lipids, including mycolic acids.

This distinctive cell wall is responsible for several key pharmacological and diagnostic features:

Acid-Fastness: The high lipid content makes the bacteria resistant to common stains, requiring the use of the Ziehl-Neelsen staining technique, hence the term Acid-Fast Bacilli (AFB).

Slow Growth: The impermeable cell wall contributes to the slow growth rate of Mtb, which complicates laboratory culture and significantly prolongs the required duration of drug treatment (typically 6 months or more).

Drug Resistance: The cell wall acts as a barrier, limiting the penetration of many antimicrobial agents, a factor contributing to the emergence of drug resistance  [2].

1.3 Pathogenesis and Transmission

TB is primarily transmitted through the airborne route. When a person with active pulmonary TB coughs, sneezes, or speaks, they expel tiny droplet nuclei containing Mtb. Infection occurs when another person inhales these droplets.

The pathogenesis involves the following key steps:

1. Infection: Inhaled bacilli reach the alveoli of the lungs.
2. Initial Immune Response: Alveolar macrophages phagocytose the Mtb bacilli. Critically, Mtb is adapted to survive and replicate within these macrophages.
3. Granuloma Formation: The host immune system attempts to contain the infection by walling off the infected macrophages and other immune cells, forming a structure called a granuloma (or tubercle). This structure is the hallmark of TB infection.

1.4 Classification of Tuberculosis:-

Tuberculosis (TB) is categorized in a few different ways, primarily based on the status of the infection and its location in the body [10, 15].

?Based on Infection Status

The most crucial classification is between Latent TB Infection (LTBI) and Active TB Disease [15]. In LTBI, the Mycobacterium tuberculosis bacteria are present but inactive, controlled by the immune system [15]. The person is asymptomatic, non-infectious, and the treatment aim is preventive therapy [21]. Conversely, Active TB Disease involves multiplying bacteria causing illness and symptoms, and it is contagious if the lungs or throat are involved [10]. The treatment aim is to cure the disease using a multi-drug regimen [22].

Based on Location in the Body

1. ?Pulmonary TB (PTB): The most common and contagious type, primarily affecting the lungs [10]. Key symptoms include a persistent cough (3+ weeks), chest pain, and coughing up blood (hemoptysis) [10].
2. ?Extrapulmonary TB (EPTB): TB that occurs outside of the lungs, often in people with weakened immune systems [10]. EPTB is usually non-contagious unless the throat/larynx is involved [10]. Examples include TB Lymphadenitis (affecting lymph nodes), Skeletal TB (Pott's Disease, affecting bones), and TB Meningitis (a severe, life-threatening form affecting the brain) [10, 19]. Miliary TB is a rare, severe form where bacteria spread throughout the body [19].

Based on Drug Resistance

1. ?Drug-Sensitive TB: Bacteria are killed by the standard first-line drugs (Isoniazid and Rifampicin) [20].
2. ?Drug-Resistant TB (DR-TB): Bacteria have evolved and no longer respond to some or all standard drugs [24]. This includes

• Multidrug-Resistant TB (MDR-TB), which is resistant to at least Isoniazid and Rifampicin [27]. The most challenging form is
• Extensively Drug-Resistant TB (XDR-TB), which is resistant to Isoniazid and Rifampicin, plus a fluoroquinolone and at least one other major second-line drug [27].

1.5 Symptoms of Tb

Tuberculosis (TB) symptoms vary depending on whether the infection is Latent or Active, and where in the body the bacteria are growing.

1. Key Symptoms of Active TB Disease

Active TB disease means the bacteria are actively growing and making you sick. The symptoms are often vague and develop slowly over weeks or months.

I. General (Systemic) Symptoms

?These symptoms can occur regardless of where the infection is located:

1. ?Unexplained Weight Loss
2. ?Loss of Appetite
3. ?Fever (often low-grade)
4. ?Night Sweats (heavy sweating during sleep)
5. ?Weakness or Fatigue (feeling tired or exhausted)
6. ?Chills

II. Pulmonary TB (TB in the Lungs) Symptoms

Since TB most commonly affects the lungs, these are the most distinct symptoms:

1. ?A bad cough that lasts 3 weeks or longer.
2. ?Chest Pain
3. ?Coughing up blood or sputum (phlegm/mucus from the lungs).
4. ?Shortness of breath (in severe cases).

2. Latent TB Infection (LTBI)

If you have Latent TB, the TB germs are in your body, but your immune system has them contained.

1. ?You have NO symptoms.
2. ?You do not feel sick.
3. ?You cannot spread TB to other people.

?However, a person with Latent TB must often be treated to prevent them from developing Active TB disease later on.

3. Extrapulmonary TB Symptoms

Extrapulmonary Tuberculosis (EPTB) refers to a TB infection located outside of the lungs, and its symptoms are highly diverse, depending on the site of involvement. However, patients often present with general, constitutional symptoms common to many forms of TB, including a persistent fever, drenching night sweats, unexplained weight loss, and general fatigue or malaise. Specific localized symptoms then emerge based on the affected organ.

TB can affect other parts of the body besides the lungs (Extrapulmonary TB) . Specific localized symptoms then emerge based on the affected organ: for example,

1. Lymph Nodes (TB Lymphadenitis) typically causes swelling of the lymph nodes, especially in the neck (often firm and painless);
2. Spine/Bones (Skeletal TB) leads to severe back pain, joint pain, stiffness, or bone deformities;
3. Brain/Meninges (TB Meningitis) presents as a persistent headache, confusion, stiff neck, nausea, and vomiting;
4. Kidneys/Urinary Tract can cause blood in the urine, pain during urination, or flank pain; and
5. Abdomen TB can cause chronic abdominal pain, swelling, or changes in bowel habits [19].

1.6  Latent vs. Active TB

Latent TB Infection (LTBI): The bacteria are contained within the granuloma. The person is asymptomatic, non-infectious, and cannot transmit the disease. Approximately one-quarter of the world’s population has LTBI. 

Active TB Disease: If the host's immune system weakens (due to HIV, age, malnutrition, etc.), the granuloma breaks down, allowing the bacteria to multiply rapidly and spread throughout the lungs and potentially to other organs. The patient becomes symptomatic and infectious. The rate of progression from LTBI to active disease is approximately 5-10\% over a lifetime  [3]  .

2.0 CURRENT TB DIAGNOSTIC METHODS

2.1 Conventional Methods (Sputum Smear Microscopy and Culture)

For decades, the foundation of Tuberculosis (TB) diagnosis has relied on conventional microbiological methods, which remain essential, particularly in resource-limited settings  [4]  

2.1.1 Sputum Smear Microscopy (Acid-Fast Bacilli - AFB Staining)

Sputum smear microscopy is the most widely available and cost-effective initial diagnostic procedure for suspected pulmonary TB  [4]  .

1. Procedure: Clinical specimens, typically sputum, are stained with specialized dyes (most commonly the Ziehl-Neelsen or fluorochrome methods) to detect Acid-Fast Bacilli (AFB), which are characteristic of M. tuberculosis  [7]  .
2. Advantages: It is rapid, inexpensive, and requires minimal infrastructure, making it suitable for developing countries  [4]  .
3. Limitations: Microscopy has low sensitivity, especially in patients with paucibacillary disease (low bacterial load), such as those who are HIV-positive or have smear-negative TB  [15]  . It also cannot differentiate between M. tuberculosis and other non-tuberculous mycobacteria (NTM)  [5]  .

2.1.2 Mycobacterial Culture

Culture is considered the gold standard for TB diagnosis because it confirms the presence of viable M. tuberculosis and allows for subsequent Drug Susceptibility Testing (DST)  [4], [7]  .

1. Procedure: Samples are inoculated onto solid media (e.g., Löwenstein-Jensen, LJ) or liquid media (e.g., BACTEC MGIT)  [5]  .
2. Advantages: It provides the highest sensitivity and specificity for TB diagnosis  [10]  . Liquid culture media have significantly increased the rapidity and sensitivity of isolation compared to solid media  [5]  .
3. Limitations: M. tuberculosis is a slow-growing organism, requiring 2 to 8 weeks to yield results on solid media, which delays treatment initiation, especially for drug-resistant cases  [7], [9]  .

2.2 Molecular Diagnostics: The Revolution in Rapid Detection

Molecular diagnostic tests, specifically Nucleic Acid Amplification Tests (NAATs), have revolutionized TB diagnosis by offering high sensitivity and rapid results, often within hours  [13]  .

2.2.1 GeneXpert MTB/RIF Assay and Xpert Ultra

The GeneXpert MTB/RIF assay is a fully automated, cartridge-based NAAT that is strongly recommended by the WHO as an initial diagnostic test  [7], [16]  .

1. Functionality: It simultaneously detects the presence of M. tuberculosis Complex (MTBC) DNA and identifies mutations associated with resistance to Rifampicin (RIF), one of the most crucial first-line anti-TB drugs  [12], [2.4]  .
2. Process: The test performs sample processing, DNA isolation, and real-time Polymerase Chain Reaction (PCR) in a single, hands-free cartridge system, providing results in less than 2 hours  [13], [14]  .
3. Clinical Impact: Rapid detection of RIF resistance is a critical predictor of Multidrug-Resistant TB (MDR-TB), allowing doctors to initiate appropriate second-line treatment much faster, leading to better patient outcomes and reduced transmission risk  [11], [12]  .
4. Xpert Ultra: The newer Xpert MTB/RIF Ultra (Xpert Ultra) was developed to improve sensitivity, particularly in smear-negative and paucibacillary patients (e.g., those with HIV co-infection), by using two different M. tuberculosis targets and incorporating melt-curve analysis  [15].

2.2.2 Line Probe Assays (LPAs)

LPAs are molecular tests that detect drug resistance mutations in M. tuberculosis bacteria. They are often used as a second-line test following initial diagnosis  [4]  .

1. Functionality: LPAs utilize PCR and reverse hybridization to rapidly detect mutations, such as those indicating resistance to Rifampicin and Isoniazid (first-line drugs), and certain second-line drugs [5].
2. Examples: Affordable LPA tests like GenoType MTBDRplus (for first-line resistance) and GenoType MTBDRsl (for second-line resistance) are widely used  [4], [5].

2.3 Immunological Tests for Latent TB Infection (LTBI)

These tests are primarily used to diagnose Latent TB Infection (LTBI), where the person is infected but asymptomatic and non-contagious. They detect the host's immune response to the bacteria rather than the live bacteria itself  [3.4], [3.6]  .

2.3.1 Tuberculin Skin Test (TST)

The Tuberculin Skin Test (TST), or Mantoux test, involves injecting a small amount of Purified Protein Derivative (PPD) intradermally into the forearm  [18], [19]  .

1. Mechanism: It is based on a delayed-type hypersensitivity (DTH) reaction. If the person has been exposed to M. tuberculosis, the immune system will mount a localized inflammatory response, which is read by measuring the induration (firm swelling) after 48 to 72 hours  [21].
2. Limitation: TST has poor specificity because the PPD antigen mixture contains proteins conserved across various mycobacterial species, including the strain used in the Bacille Calmette-Guérin (BCG) vaccine. This often results in false-positive reactions in BCG-vaccinated individuals  [20], [21].

2.3.2 Interferon-Gamma Release Assays (IGRAs)

IGRAs are blood tests that represent a more advanced approach to diagnosing LTBI  [17]  .

1. Mechanism: They measure the immune response by detecting the release of interferon-gamma (IFN-γ) from white blood cells (T-lymphocytes) when whole blood is mixed with synthetic peptides specific to M. tuberculosis antigens (ESAT-6 and CFP10)  [18], [23].
2. Advantages: Unlike TST, IGRAs are not affected by prior BCG vaccination, offering significantly higher specificity  [20], [23].

2.4 Future Diagnostic Strategies

Ongoing pharmaceutical and biotechnological research is focused on developing faster, cheaper, and more sensitive point-of-care (POC) tests, including the continued refinement of NAATs and the exploration of non-sputum-based diagnostics like urine assays for lipoarabinomannan (LAM)  [4]  .

3.0 CURRENT STANDARD CHEMOTHERAPY REGIMENS

The treatment of active Tuberculosis (TB) requires multi-drug therapy over a prolonged duration  [24]

3.1 First-Line Anti-TB Drugs

The standard regimen for drug-susceptible TB utilizes a combination of four core first-line drugs, often summarized by the acronym RIPE [20, 23]. These drugs attack the Mtb from different angles for synergistic effect and to prevent resistance [22].

1. ?Rifampicin (R) is bactericidal, inhibiting bacterial RNA polymerase, which blocks RNA synthesis [23]. Major side effects include hepatotoxicity, orange/red discoloration of bodily fluids, and significant drug interactions (as a CYP450 inducer) [23].
2. ?Isoniazid (H) is a prodrug activated by the KatG enzyme, which then inhibits the synthesis of mycolic acids essential for the cell wall [25, 26]. Side effects include hepatotoxicity and peripheral neuropathy, the latter of which is managed by co-administering Pyridoxine (Vitamin B6) [23].
3. ?Pyrazinamide (Z) is converted to pyrazinoic acid in acidic environments [23]. It is essential for sterilizing activity against semi-dormant bacilli residing in the acidic environment of granulomas by disrupting bacterial metabolism [22]. It carries a risk of hepatotoxicity and hyperuricemia (leading to gout flares) [23].
4. ?Ethambutol (E) inhibits the bacterial arabinosyl transferase enzyme, disrupting cell wall synthesis [23]. Its primary major side effect is ocular toxicity, specifically retrobulbar neuritis, which can lead to red-green color blindness [23].

The mechanism of action for Tuberculosis (TB) treatment involves a combination of drugs that attack the Mycobacterium tuberculosis bacteria at multiple, critical points, primarily targeting cell wall formation, genetic processes, and metabolic pathways.

The four first-line anti-TB drugs, often remembered by the mnemonic RIPE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), each have a distinct mechanism:

3.1.1 Mechanisms of Action for First-Line TB Drugs

1. Isoniazid (INH or H) - Inhibits Cell Wall Synthesis
   1. Mechanism: Isoniazid is a prodrug, meaning it's inactive until metabolized. Inside the M. tuberculosis bacteria, it's activated by the bacterial enzyme KatG (a catalase-peroxidase).
   2. Target: The active metabolite inhibits the synthesis of mycolic acids, which are essential, unique fatty acids that form the protective, waxy outer layer of the mycobacterial cell wall.
   3. Effect: This compromises the integrity of the cell wall, leading to the bacterium's death (bactericidal).
2. Rifampicin (RMP or R) - Inhibits RNA Synthesis
   1. Mechanism: Rifampicin directly binds to the \beta-subunit of the bacterial enzyme DNA-dependent RNA polymerase (RNAP).
   2. Target: This binding physically obstructs the process of transcription, preventing the bacteria from producing mRNA, which is necessary for making essential proteins.
   3. Effect: This inhibition stops bacterial protein synthesis and replication (bactericidal).
3. Pyrazinamide (PZA or Z) - Disrupts Bacterial Metabolism
   1. Mechanism: Pyrazinamide is a prodrug that is converted into its active form, pyrazinoic acid (POA), by a bacterial enzyme called pyrazinamide hydrolase (PncA), particularly in the acidic environment found inside macrophages and inflamed tissue.
   2. Target (Proposed): POA disrupts the membrane energy metabolism, inhibits trans-translation, and may inhibit coenzyme A synthesis, affecting the bacteria's ability to maintain its cell membrane and survive in acidic environments.
   3. Effect: It is especially effective against semi-dormant bacilli found in the acidic core of TB lesions (sterilizing activity).
4. Ethambutol (EMB or E) - Inhibits Cell Wall Synthesis

Mechanism: Ethambutol interferes with the synthesis of key components of the bacterial cell wall called arabinogalactan and lipoarabinomannan.

1. 1. Target: It inhibits the enzyme arabinogalactan transferase.
   2. Effect: This blocks cell wall assembly, preventing the bacteria from multiplying (bacteriostatic) and helps to prevent resistance from developing against the other drugs.

3.1.2 Rationale for Combination Therapy

TB is always treated with a combination of drugs for several critical reasons:

1. Synergy: The drugs attack the bacteria from different angles and in different conditions (e.g., Isoniazid works well on actively growing bacilli, while Pyrazinamide targets semi-dormant ones).
2. Preventing Resistance: M. tuberculosis can easily develop resistance to a single drug. Using multiple drugs ensures that any bacteria that develop resistance to one drug are killed by the others, leading to a much higher chance of a successful cure.

3.2 Treatment Phases: Intensive and Continuation

Standard TB treatment is divided into two sequential phases  [26].

1. Intensive Phase: Lasts 2 months and involves the combination of all four first-line drugs: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E). Its objective is rapid bacterial kill and prevention of resistance.
2. Continuation Phase: Lasts an additional 4 months and typically involves only two drugs: Isoniazid (H) and Rifampicin (R). Its objective is to eradicate remaining, slowly multiplying bacilli (persisters) and prevent relapse.

3.3 Challenges in Patient Compliance: The DOTS Strategy

Poor compliance is the primary driver of drug resistance. The Directly Observed Treatment, Short-course (DOTS) strategy requires a health worker or designated person to observe the patient swallowing their anti-TB medications daily for the entire treatment duration to ensure adherence  [27], [28]  .

4.0 The Crisis of Drug-Resistant TB (DR-TB)

The emergence and spread of drug-resistant strains of M. tuberculosis require more toxic drugs for a longer duration.

4.1 Defining MDR-TB, Pre-XDR-TB, and XDR-TB

1. Multidrug-Resistant TB (MDR-TB): Resistance to at least Rifampicin and Isoniazid  [30]  .
2. Pre-Extensively Drug-Resistant TB (Pre-XDR-TB): MDR-TB that is also resistant to any fluoroquinolone  [31]  .
3. Extensively Drug-Resistant TB (XDR-TB): MDR-TB that is also resistant to any fluoroquinolone and at least one additional Group A drug (Bedaquiline or Linezolid) [31]
4. Rifampicin-Resistant TB (RR-TB): Resistance to Rifampicin, which serves as a crucial marker for initiating MDR-TB treatment  [30]  .

4.2 Molecular Mechanisms of Drug Resistance

Drug resistance is caused by spontaneous chromosomal mutations in genes encoding drug targets or activation enzymes  [32]  .

Resistance to Rifampicin (R)

Resistance is mediated almost exclusively by mutations within the Rifampicin Resistance Determining Region (RRDR) of the rpoB gene, which encodes the \beta-subunit of RNA polymerase. These mutations prevent RIF from binding to the enzyme  [34], [35]  .

Resistance to Isoniazid (H)

INH resistance is genetically complex, primarily involving two genes:

1. Mutation in katG: Leads to a loss or reduction of the catalase-peroxidase activity needed to activate the INH pro-drug  [37]  .
2. Mutation/Overexpression in inhA: Causes changes in the drug target (enoyl acyl carrier protein reductase) or its increased production, reducing the drug’s effectiveness  [36]  .

4.3 Treatment Regimens for MDR/XDR-TB and Newer Anti-TB Drugs

Older DR-TB regimens were long (18–24 months), complex, and included injections. The new paradigm focuses on shorter, all-oral regimens.

The BPaL Regimen

The BPaL regimen is a significant breakthrough for Pre-XDR and XDR-TB, offering a treatment duration of approximately 6 to 9 months  [41], [42].

1. Composition: Bedaquiline, Pretomanid, and Linezolid (sometimes with Moxifloxacin, BPaLM).

4.4 Newer Anti-TB Drugs: Mechanism and Clinical Role

The most prominent newer agents are:

1. ?Bedaquiline (BDQ): This drug inhibits the proton pump of mycobacterial ATP synthase, blocking energy generation [28]. Its major side effects include QT interval prolongation (risk of Torsades de pointes) and hepatotoxicity [32].
2. ?Delamanid (DLM): It inhibits the synthesis of mycolic acids through a novel pathway [28]. Like BDQ, it carries a risk of QT interval prolongation, as well as peripheral neuropathy [32].
3. ?Pretomanid (PA-824): This drug has a dual action, inhibiting mycolic acid synthesis while also acting as a respiratory poison [28]. When used in combination with high-dose Linezolid (e.g., the BPaL regimen), side effects include peripheral neuropathy and myelosuppression [30].

The clinical use of BDQ and DLM necessitates frequent Electrocardiogram (ECG) and potassium monitoring due to the risk of QT prolongation [32].

2. Clinical Monitoring: The use of BDQ and DLM necessitates frequent Electrocardiogram (ECG) and potassium monitoring due to the risk of QT prolongation  [47]  .

5.0 Novel Approaches and Future Perspectives

5.1 Nanotechnology in TB Drug Delivery

Nanomedicine offers a powerful way to enhance efficacy and reduce toxicity.

1. Targeting Macrophages: Nanocarriers (e.g., liposomes) can be engineered to be specifically taken up by infected alveolar macrophages, which are the primary reservoir for M. tuberculosis  [49], [50]  . This targeted delivery concentrates the drug at the site of infection (the granuloma), reducing systemic toxicity  [48].
2. Sustained Release: Nanoparticle-based formulations allow for controlled and prolonged drug release, potentially reducing dosing frequency (e.g., to weekly), which is crucial for improving patient compliance with long-term therapy  [49].

5.2 TB Vaccine Development

The existing BCG vaccine provides inconsistent protection against adult pulmonary TB, the main source of transmission. The focus is on developing new vaccines for adolescents and adults.